In order to fully grasp the progress of clinical trials for new drug registration in China, use information technology to improve drug regulatory capabilities, and timely disclose clinical trial progress information to the public, and provide reference for new drug research and development, resource allocation, and drug review and approval, the Drug Evaluation Center has comprehensively summarized and analyzed the status of clinical trials for new drug registration in China in 2021 based on the new drug clinical trial registration information on the drug clinical trial registration and information disclosure platform, and compiled the "Annual Report on the Progress of Clinical Trials for New Drug Registration in China (2021)".
This annual report is mainly based on the clinical trial information of drugs registered in 2021, and summarizes and analyzes the overall trend changes, main characteristics, and outstanding issues of clinical trials from the perspectives of drug type, variety and target characteristics, indications, sponsor type, registration classification, trial classification, trial phase, special population trial, clinical trial leader unit, start-up time and completion status. At the same time, it compares the clinical trial registration data in the past three years and summarizes and analyzes the trend characteristics in recent years.
This is hereby announced.
Attachment: "Annual Report on the Progress of Clinical Trials for New Drug Registration in China (2021)"
National Drug Administration Drug Review Center
June 7, 2022
400-900-1882 
info@hillgene.com 
English
